U.S. FDA Approves Pfizer's HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis to prevent or r...
An Activist Investor Just Bought $1 Billion Worth of Pfizer. Here's What It Means for the Stock
There may be changes coming to this company, if the activists get their way.
Why Pfizer Stock Tumbled by Nearly 3% on Thursday
The company's latest institutional shareholder has made some troubling allegations against it.
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Pfizer threatened to sue renegade executives prior to activist schism, Starboard's Smith says
Activist Starboard Value accused Pfizer of threatening litigation against two renegade former executives that initially were supportive of the investor's turnaround campaign at the pharmaceutical g...
Pfizer's cancer drug combo improves overall survival in late-stage study
Pfizer said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of advanced prostate cancer in a late-stage study.
2 No-Brainer Healthcare Stocks to Buy With $200 Right Now
Both of these stocks should have plenty of room to run.
Former Pfizer executives not involved in Starboard's campaign against drugmaker
Pfizer's former CEO and Chair Ian Read and ex-CFO Frank D'Amelio said in a statement that they will not be involved with activist investor Starboard Value, which wants the U.S. drug giant to make c...
Former Pfizer CEO, finance chief step back from Starboard's activist campaign
Two former Pfizer executives who were previously linked to activist investor Starboard Value's campaign at the struggling drugmaker said they would step back from the push late Wednesday evening. F...
Why Pfizer Stock Popped Today
The sharp, sudden entry of an activist investor is raising hopes that change might come to the company.
Pfizer (PFE) Surges Amid Investor Talks and Legal Victory
Pfizer (PFE, Financial) experienced a 2.3% increase, reaching $29.85. The rise follows news that Pfizer's CEO plans to meet next week with key leaders from activist investor Starboard Value.
Pfizer and CVS Are Attracting Activists. Healthcare Stocks Could Rebound.
Activists appear to be calling a bottom on the two stocks.
Pfizer CEO plans to meet activist investor Starboard Value, FT reports
Pfizer CEO Albert Bourla plans to meet activist investor Starboard Value, the Financial Times reported on Tuesday, citing people familiar with the matter.
Healthy Returns: What activist Starboard's $1 billion stake means for Pfizer
Pfizer's troubles may finally be coming to a head. Meanwhile, Hims & Hers is joining S&P SmallCap 600.
Related Companies